In one of the most significant digital health financing rounds of 2025, Oura, the Finnish maker of the Oura Ring, announced a $900 million Series E financing round led by Fidelity Management & Research Company with participation from ICONIQ, Whale Rock, and Atreides, driving its valuation to approximately $11 billion.
This milestone is not just a testament to Oura’s remarkable commercial momentum, with 5.5 million rings sold and projected revenues approaching $1 billion, but also signals a broader shift in healthcare toward consumer empowerment, prevention, and personalized data insights.
Oura’s Series E represents a defining moment in the evolution of women’s health and the rise of consumer-led healthcare. Once viewed primarily as a sleep and wellness wearable, Oura has steadily transformed into a deeply personal health companion for millions of users, particularly women seeking greater understanding and agency over their own bodies. At a time when traditional healthcare remains fragmented and reactive, Oura’s growth signals a powerful shift toward proactive, data-driven health management rooted in daily lived experience.
For many women, healthcare has long been shaped by gaps in research, limited clinical time, and a lack of tools that reflect the complexity of hormonal and physiological change across life stages. Oura’s ability to continuously track biometric signals has opened a new window into patterns that were once invisible or poorly understood. These insights resonate strongly in areas like menstrual health, fertility awareness, pregnancy, and perimenopause, where subtle physiological changes can carry meaningful implications.
The company’s momentum reflects a broader redefinition of what healthcare looks like when it begins with the consumer. What makes Oura especially compelling in the context of women’s health is its potential to become a connective layer in a deeply fragmented care ecosystem. By aggregating biometric data over time and integrating with lab results and other health technologies, Oura can help transform isolated data points into a coherent, longitudinal health story. This creates an opportunity not only for personal insight, but for more meaningful conversations between women and their care teams, grounded in patterns.
The scale of Oura’s latest raise reflects investor confidence in a future where healthcare is increasingly shaped by the individual. As women continue to seek tools that align with their lived realities and long-term health goals, platforms like Oura are redefining what it means to participate in one’s own care.
Some early-stage players in women’s consumer health wearables:
Lumia Health (Series A) — Smart earring for measuring blood flow, sleep, and cycle tracking
Incora Health (Seed) — Smart earring for cycle tracking, HRV and measuring sleep
Clair (Pre-Seed) — Continuous hormone and biometric wrist wearable
